[Cardiovascular diseases in rheumatoid arthritis].
Cardiovascular diseases (CVD) are serious complications in patients with rheumatoid arthritis (RA) in its high morbidity and mortality. The risk of coronary artery disease (CAD)has been reported to relate to RA disease activity. By improvement of treatment agents and treatment strategy aiming remission or low disease activity of RA, the incidence of CAD can be decreasing. The cardiovascular morbidity may be attributed to other types of CVD such as large vessel diseases, microvascular myocardial dysfunction or arrhythmia in addition to CAD. To improve quality of life and mortality of RA patients, physicians should treat patients to prevent cardiovascular morbidity through RA disease control.
Ayako
A
Nakajima
D000068879:Adalimumab / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000188:drug therapy* / Q000401:mortality; D001688:Biological Products / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control*; D000068800:Etanercept / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D008727:Methotrexate / Q000627:therapeutic use; D058990:Molecular Targeted Therapy; D009017:Morbidity; D011379:Prognosis; D011788:Quality of Life
D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D001688:Biological Products; D000068879:Adalimumab; C502936:tocilizumab; D000068800:Etanercept; D008727:Methotrexate